Corcept sues to block Teva label for allegedly inducing patented Korlym dosing

Corcept seeks court order to block Teva label it says would induce patented dosing

Label wording, not chemistry, is at the heart of Corcept Therapeutics’ latest legal challenge against Teva Pharmaceutical Industries over a planned generic of Korlym, the company says. Corcept contends Teva’s proposed prescribing information effectively directs physicians to co‑administer mifepristone with potent CYP3A inhibitors such as ketoconazole in dosing relationships that Corcept treats as its patented method. The company argues that even though Teva’s product is chemically identical to Korlym, the label’s content would steer clinical practice toward methods covered by Corcept’s patents, creating a risk of induced infringement.

In filings, Corcept asserts the contested language goes beyond routine safety guidance and amounts to instructions that would encourage the precise combinations and timing of mifepristone and strong CYP3A inhibitors that its patents claim. The dispute centers on how labeling informs physician prescribing behavior: Corcept says Teva’s approval with that wording would be a practical conduit for third parties to adopt the patented dosing approach, thereby undermining Corcept’s exclusive rights to that method. The company is seeking judicial relief to prevent Teva from using the label while the patent issues remain contested.

The case highlights a legal fault line between generic market entry and method‑of‑use patent protections in specialty endocrinology drugs. Corcept frames the fight as protecting innovation in tailored dosing strategies intended to manage drug exposure and therapeutic effect, asserting that permitting the label would set a precedent allowing generic labels to induce use of patented treatment regimens. Teva’s position and any regulatory response from the U.S. Food and Drug Administration will shape whether prescribing practices shift as Corcept warns and whether courts limit the extent to which labeling can be used to promote or instruct on patented methods.

Regulatory and patient‑access implications are immediate concerns: a court block or label revision could delay generic availability for patients with Cushing’s syndrome, while a ruling for Teva could broaden avenues for generics to carry similar instructions. Corcept emphasizes that its action aims both to preserve patent value and to ensure that method‑of‑use claims remain enforceable against inducement carried through labeling.

Broader industry observers say the outcome may influence future disputes over instructions in generic labels where method patents exist, affecting how innovators draft claims and how generics craft safe‑harbor labeling to avoid inducement allegations. The case is likely to attract attention from drug developers, generics makers and regulators watching the balance between competition and protection of therapeutic‑method inventions.